ArticleNephrology (Carlton, Vic.)2025
Increased Incidence and Severity of Acute Poststreptococcal Glomerulonephritis in the Czech Paediatric Population Following the COVID-19 Pandemic.
Article in Nephrology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Increased Incidence and Severity of Acute Poststreptococcal Glomerulonephritis in the Czech Paediatric Population Following the COVID-19 Pandemic.Nephrology (Carlton, Vic.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
aimThis study aimed to investigate the incidence and severity of acute poststreptococcal glomerulonephritis (APSGN) in the Czech paediatric population before, during and after the coronavirus disease 2019 (COVID-19) pandemic.
methodsThe data were collected from 15 centres. The patients were divided into three periods: 2016-2019 (pre-COVID), 2020-2021 (COVID) and 2022-2023 (post-COVID). The incidence of APSGN during the studied period was assessed. The clinical and laboratory parameters were compared between the pre-COVID and post-COVID periods.
resultsOf the 117 patients with possible APSGN, 95 met the inclusion criteria. There were 67 (70.5%) males. The incidence of APSGN was significantly higher during the post-COVID period (32/year) than during the pre-COVID (6/year) and COVID (3.5/year) periods (p < 0.0001). The highest number of cases occurred in 2023 (n = 55). During the post-COVID period there was more frequent use (p = 0.0448) and duration (p = 0.0131) of furosemide; more frequent antihypertensive treatment (p = 0.0104); and a higher prevalence of acute kidney injury (p = 0.0145), hypertension (p = 0.0178), and hypertension stage 2 (p = 0.0372) compared to the pre-COVID period. Kidney replacement therapy and crescentic glomerulonephritis were found only during the post-COVID period.
conclusionWe found a significantly higher incidence of APSGN and its associated complications during the post-COVID period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.